Literature DB >> 9616875

Immunity to vaginal infection by herpes simplex virus type 2 in adult mice: characterization of the immunoglobulins in vaginal mucus.

E L Parr1, J J Bozzola, M B Parr.   

Abstract

Progestin-treated female mice are susceptible to vaginal infection by two sexually transmitted disease organisms: herpes simplex virus type 2 (HSV-2) and Chlamydia trachomatis. Vaccination of mice with HSV-2 or chlamydial antigens elicits immunity to vaginal infection that may be due in part to secreted antibodies in the vaginal lumen. Analysis of the role of these antibodies in immunity would be aided by information about the vaginal secretion in progestin-treated mice and the antibodies it contains. Gross and histologic observations of progestin-treated mice that were immune to vaginal HSV-2 infection indicated that the vaginal lumen was filled with mucus. A procedure for extraction of immunoglobulin from the mucus was developed and shown to recover at least 98% of the secretory IgA (S-IgA) that was free to diffuse from the mucus. Immunoblotting revealed that the predominant molecular form of IgA in vaginal mucus was dimeric S-IgA. Immunoglobulin concentrations in vaginal secretions were higher in immune mice than in non-immune mice and S-IgA concentrations were higher than those of IgG. The IgG concentration in vaginal secretions of immune mice was 4.5-fold higher than in non-immune mice, while serum IgG increased only 1.5-fold, suggesting local production of IgG or increased transudation in immune mice. Specific IgG antibody to HSV-2 was demonstrated in vaginal secretions of immune mice at a mean ELISA titer of 6200, whereas the titer of specific S-IgA in the same secretions was only 1.9. Thus, while the predominant immunoglobulin by weight in the vaginal mucus of immune mice was S-IgA, the ELISA titers suggested that the virus-specific antibody was almost entirely IgG.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9616875     DOI: 10.1016/s0165-0378(97)00081-8

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  17 in total

1.  Immune responses and protection against vaginal infection after nasal or vaginal immunization with attenuated herpes simplex virus type-2.

Authors:  E L Parr; M B Parr
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

2.  Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells.

Authors:  L A Morrison; L Zhu; L G Thebeau
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  Immunoglobulin G, plasma cells, and lymphocytes in the murine vagina after vaginal or parenteral immunization with attenuated herpes simplex virus type 2.

Authors:  E L Parr; M B Parr
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

4.  Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection.

Authors:  Zili Li; Senthilkumar Palaniyandi; Rongyu Zeng; Wenbin Tuo; Derry C Roopenian; Xiaoping Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-28       Impact factor: 11.205

5.  Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization.

Authors:  D Chen; S B Periwal; K Larrivee; C Zuleger; C A Erickson; R L Endres; L G Payne
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

6.  Zika virus preferentially replicates in the female reproductive tract after vaginal inoculation of rhesus macaques.

Authors:  Timothy Carroll; Ming Lo; Marion Lanteri; Joseph Dutra; Katie Zarbock; Paola Silveira; Tracy Rourke; Zhong-Min Ma; Linda Fritts; Shelby O'Connor; Michael Busch; Christopher J Miller
Journal:  PLoS Pathog       Date:  2017-07-26       Impact factor: 6.823

Review 7.  Vaccines against genital herpes: progress and limitations.

Authors:  Lynda A Morrison
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  Mucosal innate and adaptive immune responses against herpes simplex virus type 2 in a humanized mouse model.

Authors:  Amanda Kwant-Mitchell; Ali A Ashkar; Kenneth L Rosenthal
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

9.  Replication-defective virus vaccine-induced protection of mice from genital herpes simplex virus 2 requires CD4 T cells.

Authors:  Lynda A Morrison
Journal:  Virology       Date:  2008-04-14       Impact factor: 3.616

10.  Mucosal and systemic immune responses to a human immunodeficiency virus type 1 epitope induced upon vaginal infection with a recombinant influenza A virus.

Authors:  Bruno Garulli; Yoshihiro Kawaoka; Maria R Castrucci
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.